Integrated Microfluidic LC-MS - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Integrated Microfluidic LC-MS
The authors describe a new microfluidic-based workflow that integrates and automates glycan cleaveage, purification, and chromatographic separation onto a microfluidic liquid chromatography–mass spectrometry chip for MS detection.

Pharmaceutical Technology
Volume 34, pp. s32-s39


Until today, N-Linked glycan characterization workflows were tedious and time-consuming, making them unsuitable for real-time bioprocessing applications. A microfluidic LC–MS chip approach is described that integrates and automates all analysis steps: glycan cleavage, capture and purification, chromatographic separation, and MS detection. This approach reduces the previously lengthy incubation time for deglycosylation with PNGase F from many hours to 6 s. It eliminates reaction steps, including acidification, labeling, or derivatizing the free glycans used with traditional LC and MS approaches. Sample cleanup and labeling steps common to LIF detection, and acidification and desalting steps common to MALDI-TOF-MS are not needed. Rapid TOF-MS detection following deglycosylation makes it possible to measure -glycosylamine intermediates directly. Compared with measuring free reducing end glycans, this approach provided the advantages of simpler chromatographic peaks, isomer detection, and enhanced sensitivity.

In total, the integrated microfluidic LC–MS chip reduces analysis time from antibody injection to LC–MS results to 10 min and is completely automated once sample is introduced. It was also shown to separate isomers quickly and efficiently. The chip has the advantage of being able to characterize very complex glycan profiles. Low-level, unknown and nonfucosylated glycans were easily identified. Using a different LC–MS chip configuration, it is possible to analyze the deglycosylated antibody. The authors believe that this microfludic LC–MS chip-based workflow will facilitate fast and accurate glycan characterization in all stages of glycoprotein development and processing.

Maggie Bynum* is a scientist at Agilent Technologies' Agilent Laboratories, 5301 Stevens Creek Blvd, Santa Clara, CA 95051, tel. 408.553.3152, fax 408.553.2161,
. Tomasz Baginski is a scientist, and Rodney Keck is a senior scientist and senior group leader at Genentech. Kevin Killeen is a director at Agilent Technologies' Agilent Laboratories.

*To whom all correspondence should be addressed.


1. R.L. Shields et al., J. Biol. Chem. 277 (30), 26733–26740 (2002).

2. C.H. Chung et al., New Eng. J. Med. 358 (11), 1109–1117 ( 2008).

3. B.S. Kendrick et al., BioPharm Intl. 22 (8), 32–44 (2009).

4. P. Hermentin et al., Anal. Biochem, 203 (2), 281–289 (1992).

5. K.R. Anumula, Anal. Biochem. 283 (1), 17–26 (2000).

6. A. Guttman et al., Anal. Biochem. 233 (2), 234–242 (1996).

7. D.I. Papac et al., Glycobiology 8 (5), 445–454 (1998).

8. L.A. Gennaro and O. Salas-Solano, Anal. Chem. 80 (10), 3838–3845 (2008).

9. G.R. Guile et al., Anal. Biochem. 240 (2), 210–226 (1996).

10. M. Wuhrer et al., Mass Spec. Rev. 28 (2), 192–206 (2009).

11. M.R. Ninonuevo et. al., Agric. Food Chem. 54 (20), 7471–7480 (2006).

12. N. Tao et al, J. Dairy. Sci. 92 (7), 2991–3001 (2009).

13. M.A. Bynum et al., Anal. Chem. 81 (21), 8818–8825 (2009).

14. H. Yin et al., Anal. Chem, 77 (2), 527–533 (2005).

15. Consortium for Functional Glycomics,, accessed Feb. 18, 2010.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here